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Lung transplantation (LTx) remains the only therapeutic
strategy for the treatment of end-stage respiratory failure in
selected patients [1,2]. However, clinical scenario of LTx is
rapidly changing. Two aspects still characterize LTx in
comparison with the transplant of other solid organs. First,
only a limited number of lung grafts is considered suitable
for transplant within the donors’ pool. Secondly, patients
quickly deteriorating while on the waiting list cannot be
bridged for long periods [3]. These limitations result in a
long period and a high mortality rate on the waiting list.
Different strategies have been proposed to overcome these
problems. Among those, the ex vivo lung perfusion (EVLP)
appears the most promising one. Several lung transplant
centers have been implemented with an EVLP program
worldwide. EVLP is applied to evaluate and eventually
recondition marginal or even initially rejected grafts, allow-
ing an increase of transplanted grafts with clinical results as
good as those obtained with the use of “standard” lungs
[4,5].
Despite the effect of such strategies, the mismatch
between the request and the offer still remains and the
donor/recipient matching plays a crucial role to achieve the
optimal risk/benefit ratio after transplant. Rapidly deterio-
rating patients waiting for lung transplant can be supported
with mechanical ventilation and/or extracorporeal lung
support (by means of extracorporeal circulatory membrane
oxygenation or CO2 removal devices) only for a limited
period of time, and LTx remains the definitive therapy.
Therefore, critically ill patients suffering from severe hyper-
capnic or hypoxic respiratory insufficiency represent a real
challenge in LTx.
Ethical and clinical concerns arise when lungs are trans-
planted in supported patients because of the higher risk of
transplant failure directly related to the critical status of the
recipient. On the other hand, emergency LTx represents the
only survival chance for these patients. In addition, emer-
gency transplantation can reduce the number of grafts
employed for standard cases loosing the survival benefit of
elective procedure.
In the paper entitled “Extracorporeal CO2-removal as
bridge to lung transplantation in life-threatening hypercap-
nia”, Schellongowski P. et al. [6] describe optimal results
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both in terms of transplant rate and of survival with the use
of CO2-removal devices as a bridge to LTx in patients with
severe hypercapnia.
Excellent clinical outcomes of transplant performed on
supported patients are due to several reasons. The first one
is the availability of more reliable technologies such as
polymethylpentene oxygenators, heparin-coated circuits,
double-lumen cannulas, pumpless technologies, and
new-generation centrifugal pumps. Technological improve-
ments allow a wider and an earlier application of extracor-
poreal support, reducing the need of mechanical
ventilation that is considered a significant detrimental risk
factor. As these technologies are applicable only for short
periods of time, organ procurement organizations should
be able to offer a suitable graft in a reasonable period of
time. This aspect is clearly evident in the Italian experience.
Few years ago, we reported our initial results with CO2
removal devices in patients awaiting lung transplantation
[7]. The efficacy of these devices in the short term was
clearly demonstrated; however, transplant rate was only
25%. At that time, a proper protocol of prioritization was
not active in Italy and the chance for supported patients to
be transplanted was the same as for elective patients. In
November 2010, a national protocol of lung transplant pri-
ority has been activated in Italy. The preliminary analysis of
this program has shown a 79% transplant rate (after a
mean period of urgent waiting list of nearly 10 days) with
acceptable medium-term results (30-day, 6-month, and 1-
year survival rates of 81.8, 76.2, and 71.4%, respectively)
[8]. Bridge to lung transplant strategy is therefore feasible,
but it relies on the availability of a graft in a relative short
period of time. Another critical point is the accurate selec-
tion of the candidate in terms of transplant suitability.
Although not fully demonstrated, a common feeling is that
morbidity and mortality of LTx are much more recipient
related than donor related. A more aggressive strategy of
support, in an early phase of the disease, can be helpful to
preserve multi-organ function and to reduce the risk of
multi-organ failure. This allows to keep the of risk/benefit
ratio of transplant in the favor of benefit.
The experience reported by Schellongowski P. et al. is
absolutely valuable, and it demonstrates a significant pro-
gress in the treatment of end-stage respiratory failure. For
this reason, the authors must be congratulated for provid-
ing such good results.
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